Related references
Note: Only part of the references are listed.A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
DNA Methylation in T-Cell Acute Lymphoblastic Leukemia: In Search for Clinical and Biological Meaning
Natalia Mackowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy et al.
FRONTIERS IN IMMUNOLOGY (2021)
Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
Guangjie Zhao et al.
FRONTIERS IN ONCOLOGY (2021)
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Julia Stomper et al.
LEUKEMIA (2021)
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor
Lei Huang et al.
PLOS ONE (2021)
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup
Aurore Touzart et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
Raffaele Palmieri et al.
CANCERS (2020)
5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
Nancy D. Ebelt et al.
FRONTIERS IN IMMUNOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
Victoria E. Sanchez et al.
SCIENTIFIC REPORTS (2020)
Humanized Rodent Models for Cancer Research
Huimin Tian et al.
FRONTIERS IN ONCOLOGY (2020)
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
Myrna R. Nahas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Epigenetic therapies in acute myeloid leukemia: where to from here?
Katie A. Fennell et al.
BLOOD (2019)
An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
Taisen Hao et al.
SCIENTIFIC REPORTS (2019)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naval G. Daver et al.
BLOOD (2019)
Murine Models of Acute Myeloid Leukaemia
Marwa Almosailleakh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Na Luo et al.
NATURE COMMUNICATIONS (2018)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Liru Wang et al.
ONCOIMMUNOLOGY (2018)
Acute myeloid leukemia: 2019 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypomethylating Agents as a Therapy for AML
Claude Gardin et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer
V. P. Baklaushev et al.
SCIENTIFIC REPORTS (2017)
Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia
Na Shen et al.
CLINICAL CANCER RESEARCH (2017)
An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia
Hui Sun et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Cellular Immune Response Against Firefly Luciferase After Sleeping Beauty-Mediated Gene Transfer In Vivo
Kelly M. Podetz-Pedersen et al.
HUMAN GENE THERAPY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding
Till Schoofs et al.
BLOOD (2013)
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Benedetta Costantini et al.
HAEMATOLOGICA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
Gillian M. Keating
DRUGS (2012)
Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications forin vitroModeling of Chemoimmunotherapy
Yong-Rim Kwon et al.
Immune Network (2012)
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Long Zhang et al.
BLOOD (2009)
Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell line isolation
Weimin L. Kaufman et al.
NUCLEIC ACIDS RESEARCH (2008)
Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome
H Chang et al.
LEUKEMIA RESEARCH (2004)
Share Paper
